We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

83 hedge funds and large institutions have $2.86B invested in MoonLake Immunotherapeutics in 2023 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

571% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 7

400% more funds holding in top 10

Funds holding in top 10: 2 → 10 (+8)

239% more capital invested

Capital invested by funds: $843M → $2.86B (+$2.02B)

213% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 8

93% more funds holding

Funds holding: 43 → 83 (+40)

27.75% more ownership

Funds ownership: 100.69% → 128.44% (+28%)

Holders
83
Holders Change
+40
Holders Change %
+93.02%
% of All Funds
1.3%
Holding in Top 10
10
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+400%
% of All Funds
0.16%
New
47
Increased
25
Reduced
8
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$78.1M
2
ACA
Avoro Capital Advisors
New York
+$46.4M
3
CAM
Cormorant Asset Management
Massachusetts
+$33.6M
4
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$30.9M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$29.9M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$24.3M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$7.98M
3
GPP
Great Point Partners
Connecticut
-$5.95M
4
Axa
Axa
France
-$3.94M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
VEA
76
Virtus ETF Advisers
New York
$207K +$109K +4,053 New
DWA
77
Dorsey Wright & Associates
California
$56.7K +$2.99K +111 +11%
TRCT
78
Tower Research Capital (TRC)
New York
$46.5K +$24.5K +912 New
Osaic Holdings
79
Osaic Holdings
Arizona
$41K +$19.6K +727 +957%
Citigroup
80
Citigroup
New York
$30.8K -$2.06M -76,673 -99%
New York State Common Retirement Fund
81
New York State Common Retirement Fund
New York
$8.41K +$4.44K +165 New
PTC
82
Private Trust Company
Ohio
$1.73K +$915 +34 New
Allianz Asset Management
83
Allianz Asset Management
Germany
$224 +$118K +4,400 New
GPP
84
Great Point Partners
Connecticut
– -$5.95M -278,334 Closed
CSS
85
Cubist Systematic Strategies
Connecticut
– -$1.28M -59,858 Closed
Point72 Asset Management
86
Point72 Asset Management
Connecticut
– -$636K -29,748 Closed
Jane Street
87
Jane Street
New York
– -$557K -26,034 Closed
BHCM
88
Boulder Hill Capital Management
New York
– -$310K -14,500 Closed
Ensign Peak Advisors
89
Ensign Peak Advisors
Utah
– -$248K -11,575 Closed
UBS Group
90
UBS Group
Switzerland
– -$170K -7,960 Closed
1 2 3
4

MLTX Hedge Fund Activity: Q2 2023 in Review

83 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2023, worth a combined $2.86B — up 239% from $843M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new MLTX positions and 7 closed out — a net gain of 40 holders — while 25 added to existing stakes and 8 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $78.1M. The largest seller was Citadel Advisors, cutting an estimated $24.3M.

  • 83 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2023, up from 43 in Q1 2023.
  • Funds reported $2.86B of MoonLake Immunotherapeutics stock for Q2 2023, up 239% quarter-over-quarter.
  • 47 funds opened new MoonLake Immunotherapeutics positions in Q2 2023 and 7 closed out, a net change of +40 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $78.1M added.
  • The largest MoonLake Immunotherapeutics seller in Q2 2023 was Citadel Advisors, an estimated $24.3M sold.

Based on aggregated 13F filings for Q2 2023.